Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloInstituto Multidisciplinario de Biología Celular es
cic.versioninfo:eu-repo/semantics/publishedVersiones
dc.date.accessioned2016-06-21T16:06:54Z
dc.date.available2016-06-21T16:06:54Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/2280
dc.titleSensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibitionen
dc.typeArtículoes
dcterms.abstractAim of study: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5‑fluorouracil (5‑FU) on colon cancer. Materials and Methods: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. Results: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. Conclusion: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.en
dcterms.creator.authorRichard, Silvina Marieles
dcterms.creator.authorMartinez Marignac, Verónica L.es
dcterms.extentp. 336-340es
dcterms.identifier.otherDOI 10.4103/0973-1482.157317es
dcterms.identifier.urlDocumento completoes
dcterms.isPartOf.issuevol. 11, nº 2es
dcterms.isPartOf.seriesJournal of Cancer Research and Therapeuticses
dcterms.issued2015-06
dcterms.languageIngléses
dcterms.licenseAttribution 4.0 International (BY 4.0)es
dcterms.publisherAssociation of Radiation Oncologists of Indiaes
dcterms.subjectNeoplasias Colorrectaleses
dcterms.subjectMetforminaes
dcterms.subjectoxaliplatinoes
dcterms.subjectRibavirinaes
dcterms.subject.materiaBiología Celular, Microbiologíaes

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Sensitization_to_oxaliplatin_bitstream_5578.pdf-PDFA.pdf
Tamaño:
587.31 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo